Epoprostenol: interakcje
Epoprostenol (Flolan, Veletri), analog prostaglandyny: 162 udokumentowane interakcje w indeksowanych przez nas etykietach FDA i kartach informacyjnych. Poważne: 13, umiarkowane: 141, niewielkie: 8, pary, dla których etykieta nie zgłasza istotnej interakcji: 0. Każda pozycja poniżej cytuje zdanie, na którym się opiera. Ta strona leku to punkt wyjścia, a nie rozstrzygnięcie dla indywidualnej sytuacji.
Interakcje z etykiety
Poważne interakcje (13)
Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (etykieta leku Epoprostenol, Ostrzeżenia i środki ostrożności)
Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (etykieta leku Epoprostenol, Ostrzeżenia i środki ostrożności)
Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (etykieta leku Epoprostenol, Ostrzeżenia i środki ostrożności)
Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (etykieta leku Epoprostenol, Ostrzeżenia i środki ostrożności)
…fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.8 , 5.9) ] • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium and misoprostol, other prostaglandins, or any components of the drug product [see Warnings and Precautions (5.8 , 5.10) ] • Pregnancy ( 4 ) (etykieta leku Diklofenak + mizoprostol, Przeciwwskazania)
Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (etykieta leku Epoprostenol, Ostrzeżenia i środki ostrożności)
Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (etykieta leku Epoprostenol, Ostrzeżenia i środki ostrożności)
Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (etykieta leku Epoprostenol, Ostrzeżenia i środki ostrożności)
Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (etykieta leku Epoprostenol, Ostrzeżenia i środki ostrożności)
Ketorolac tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage. (etykieta leku Ketorolak, Przeciwwskazania)
The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (etykieta leku Latanoprost, Interakcje z innymi lekami)
Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (etykieta leku Epoprostenol, Ostrzeżenia i środki ostrożności)
Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (etykieta leku Epoprostenol, Ostrzeżenia i środki ostrożności)
Umiarkowane interakcje (141)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Hypotension Adenosine injection is a potent peripheral vasodilator and can induce significant hypotension. (etykieta leku Adenozyna, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (etykieta leku Awanafil, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Celekoksyb, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
• Co-administration with Other Vasodilators or Negative Chronotropic Agents : Use with caution due to additive pharmacodynamic effects. (etykieta leku Deksmedetomidyna, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Diflunisal, Ostrzeżenia)
In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with epoprostenol was initiated, apparent oral clearance values for furosemide (n=23) and digoxin (n=30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Diklofenak, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Etodolak, Ostrzeżenia)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Fenoprofen, Ostrzeżenia i środki ostrożności)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Flurbiprofen, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with epoprostenol was initiated, apparent oral clearance values for furosemide (n=23) and digoxin (n=30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal Toxicity and Hyperkalemia Renal Toxicity Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Hydrokodon + ibuprofen, Ostrzeżenia)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Ibuprofen, Ostrzeżenia i środki ostrożności)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Ibuprofen + famotydyna, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Indometacyna, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (etykieta leku Ketoprofen, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Kwas mefenamowy, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Meloksykam, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Nabumeton, Ostrzeżenia)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Naproksen, Ostrzeżenia i środki ostrożności)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Naproksen + ezomeprazol, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Oksaprozyna, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Paracetamol + ibuprofen, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Piroksykam, Ostrzeżenia i środki ostrożności)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Salsalat, Ostrzeżenia)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion.In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. (etykieta leku Sulindak, Ostrzeżenia)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)
Blood Pressure Decreases Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including SILDENAFIL ORAL FILM. (etykieta leku Syldenafil, Ostrzeżenia i środki ostrożności)
When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (etykieta leku Tadalafil, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Tolmetyna, Ostrzeżenia)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (etykieta leku Wardenafil, Ostrzeżenia i środki ostrożności)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etykieta leku Epoprostenol, Interakcje z innymi lekami)
Wzmianki o niewielkim znaczeniu (8)
Drugs antagonizing pressor effects of epinephrine α-blockers, such as phentolamine Vasodilators, such as nitrates Diuretics Antihypertensives Ergot alkaloids Drugs potentiating pressor effects of epinephrine • Sympathomimetics • β-blockers, such as propranolol • Tricyclic anti-depressants • Monoamine oxidase (MAO) inhibitors • Catechol-O-methyl transferase (COMT)… (etykieta leku Adrenalina, Interakcje z innymi lekami)
Phosphodiesterase-5 (PDE5) Inhibitors: PDE5-inhibitors are also vasodilators. (etykieta leku Alfuzosyna, Ostrzeżenia i środki ostrożności)
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (etykieta leku Chlorek potasu, Interakcje z innymi lekami)
Alpha-adrenergic antagonists and PDE-5 inhibitors are both vasodilators that can lower blood pressure. (etykieta leku Dutasteryd + tamsulosyna, Ostrzeżenia i środki ostrożności)
Evidence from animal studies has suggested that certain other prostaglandins have some teratogenic potential. (etykieta leku Karboprost, Ostrzeżenia)
Post injury arterial injection of vasodilators and/or arterial infusion of parenteral fluids are generally regarded to be of no value in altering outcome. (etykieta leku Metoheksital, Ostrzeżenia)
Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (etykieta leku Sylodosyna, Ostrzeżenia i środki ostrożności)
Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (etykieta leku Tamsulosyna, Ostrzeżenia i środki ostrożności)
Sprawdź, jak Epoprostenol łączy się ze wszystkim, co przyjmujesz. Dodaj całą listę; wszystkie pary są sprawdzane jednocześnie.
Otwórz w wyszukiwarceTo nie jest porada medyczna. Stopień nasilenia odzwierciedla sformułowania etykiety, a nie indywidualne okoliczności. Oznaczenie „poważna” może dotyczyć połączenia stosowanego rutynowo pod nadzorem, a „niewielka” może mieć znaczenie przy dużych dawkach. Należy zapytać farmaceutę.